Brenig Therapeutics
Pioneering Breakthrough Treatments for Neurodegenerative Diseases
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
About
Brenig Therapeutics is a clinical-stage biotechnology company pioneering the development of best-in-class, brain-penetrant small-molecule therapies for neurodegenerative diseases. Co-founded in 2021 by OrbiMed and Torrey Pines Investment with European scientific leadership, Brenig's lead program BT-267 is a LRRK2 inhibitor in Phase 1 clinical trials for Parkinson's disease. The company leverages its European science base and deep expertise in neuroinflammation to build a pipeline targeting high-unmet-need neurological conditions where existing treatments have failed.
Summary
Brenig Therapeutics is a Biotech company, founded in 2021.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...